Harvard Apparatus Regenerative Technology’s (HART) Lab-Grown Organ Technology Featured in MIT Technology Review

Clinical-stage biotechnology company Harvard Apparatus Regenerative Technology, Inc. announced it has been featured in an article published by MIT Technology Review that was published on Jan. 16, 2014.

Entitled “Manufacturing Organs,” the article highlighted HART’s new focus and noted the company is increasing its production of synthetic tracheas to supply clinical trials.

HART has given eight patients a new chance at life since 2008, the article said, as surgeons have replaced the patients’ badly damaged tracheas with manmade tracheas from HART. The company’s experimental technology is now transitioning from research labs to a Boston-area manufacturing facility as HART gets ready to produce the scaffolds needed to grow these synthetic organs on a large scale. The company is testing its synthetic trachea system in Russia and has plans in view for tests in the European Union and the United States.

HART’s synthetic tracheas are created using a patient’s own stem cells – and the technology could be adapted for creating other organs in the future, potentially meeting a huge and critical medical need for thousands of patients who are waiting for organ transplants.

The article can be viewed in its entirety at http://www.technologyreview.com/news/522576/manufacturing-organs/

For more information, visit HART’s website at www.harvardapparatusregen.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html